- MedExpress has launched generic semaglutide in Canada following Health Canada’s approval of generic versions of the GLP-1 therapy, expanding lower-cost treatment options for eligible patients.
- The clinician-led online consultation platform said the treatment contains the same active ingredient as branded semaglutide medicines and is expected to deliver similar therapeutic effects at a more affordable price point.
- MedExpress Canada is offering the prescription treatment starting at CAD $124.99, with consultations, eligibility assessments, and discreet shipping available through its digital platform across Alberta, British Columbia, and Ontario.
- The company noted that all generic semaglutide products authorized in Canada must meet Health Canada’s safety and quality standards, with MedExpress physicians overseeing prescribing and patient support throughout treatment.
Takeaways
MedExpress is adding another low-cost telehealth channel for generic semaglutide in Canada, which should increase competition among virtual clinics and make GLP‑1 access even easier for eligible patients in Alberta, British Columbia, and Ontario. With pricing starting at CAD 124.99 and clinician oversight built in, it can help pull more demand into online care rather than traditional clinics.
The bigger market effect is more price pressure on branded semaglutide and on other Canadian telehealth platforms offering the same drug, especially as Health Canada-approved generics become more widely available. If patients keep choosing these lower-cost digital options, semaglutide could move faster from a premium weight-loss product to a more mainstream metabolic therapy in Canada.
Source: CA Newswire
